Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at ...

Below is a chart showing MA's trailing twelve month trading history, with the $545 strike highlighted in orange: And Neurocrine Biosciences, Inc. (Symbol: NBIX) saw options trading volume of 6,125 ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

Analysts' ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the last quarter vary from bullish to bearish, as provided by 15 analysts. The table below offers a condensed view of their recent ...

Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares ...

EIRY ROBERTS, the Chief Medical Officer of $NBIX, sold 500 shares of the company on 02-14-2025 for an estimated $57,521. We received data on the trade from a recent ...

$NBIX insiders have traded $NBIX stock on the open market 48 times in the past 6 months. Of those trades, 0 have been purchases and 48 have been sales. Here’s a ...

Darin Lippoldt, the Chief Legal Officer of $NBIX, sold 1,086 shares of the company on 02-13-2025 for an estimated $126,789. We received data on the trade from a ...